Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Methodology

An accelerated mouse model for atherosclerosis and adipose tissue inflammation

Authors: Angelika Neuhofer, Bernhard Wernly, Lukas Leitner, Alisina Sarabi, Nicole G Sommer, Günther Staffler, Maximilian Zeyda, Thomas M Stulnig

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Obesity and particularly the metabolic syndrome, which is often associated with obesity, combine a major risk for type 2 diabetes and cardiovascular disease. Emerging evidence indicate obesity-associated subclinical inflammation primarily originating from adipose tissue as a common cause for type 2 diabetes and cardiovascular disease. However, a suitable and well-characterized mouse model to simultaneously study obesity-associated metabolic disorders and atherosclerosis is not available yet. Here we established and characterized a murine model combining diet-induced obesity and associated adipose tissue inflammation and metabolic deteriorations as well as atherosclerosis, hence reflecting the human situation of cardio-metabolic disease.

Methods

We compared a common high-fat diet with 0.15% cholesterol (HFC), and a high-fat, high-sucrose diet with 0.15% cholesterol (HFSC) fed to LDL receptor-deficient (LDLR-/-) mice. Insulin resistance, glucose tolerance, atherosclerotic lesion formation, hepatic lipid accumulation, and inflammatory gene expression in adipose tissue and liver were assessed.

Results

After 12–16 weeks, LDLR-/- mice fed HFSC or HFC developed significant diet-induced obesity, adipose tissue inflammation, insulin resistance, and impaired glucose tolerance compared to lean controls. Notably, HFSC-fed mice developed significantly higher adipose tissue inflammation in parallel with significantly elevated atherosclerotic lesion area compared to those on HFC. Moreover, LDLR-/- mice on HFSC showed increased insulin resistance and impaired glucose tolerance relative to those on HFC. After prolonged feeding (20 weeks), however, no significant differences in inflammatory and metabolic parameters as well as atherosclerotic lesion formation were detectable any more between LDLR-/- mice fed HFSC or HFC.

Conclusion

The use of high sucrose rather than more complex carbohydrates in high-fat diets significantly accelerates development of obesity-driven metabolic complications and atherosclerotic plaque formation parallel to obesity-induced adipose tissue inflammation in LDLR-/- mice. Hence LDLR-/- mice fed high-fat high-sucrose cholesterol-enriched diet appear to be a suitable and time-saving animal model for cardio-metabolic disease. Moreover our results support the suggested interrelation between adipose tissue inflammation and atherosclerotic plaque formation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120 (16): 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120 (16): 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
3.
go back to reference An X, Yu D, Zhang R, Zhu J, Du R, Shi Y, Xiong X: Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol. 2012, 11: 71-10.1186/1475-2840-11-71.PubMedCentralCrossRefPubMed An X, Yu D, Zhang R, Zhu J, Du R, Shi Y, Xiong X: Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol. 2012, 11: 71-10.1186/1475-2840-11-71.PubMedCentralCrossRefPubMed
5.
go back to reference Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444 (7121): 860-867. 10.1038/nature05485.CrossRefPubMed Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444 (7121): 860-867. 10.1038/nature05485.CrossRefPubMed
6.
go back to reference Zeyda M, Stulnig TM: Obesity, inflammation, and insulin resistance–a mini-review. Gerontology. 2009, 55 (4): 379-386. 10.1159/000212758.CrossRefPubMed Zeyda M, Stulnig TM: Obesity, inflammation, and insulin resistance–a mini-review. Gerontology. 2009, 55 (4): 379-386. 10.1159/000212758.CrossRefPubMed
7.
go back to reference Osborn O, Olefsky JM: The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012, 18 (3): 363-374. 10.1038/nm.2627.CrossRefPubMed Osborn O, Olefsky JM: The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012, 18 (3): 363-374. 10.1038/nm.2627.CrossRefPubMed
8.
go back to reference Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112 (12): 1796-1808.PubMedCentralCrossRefPubMed Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112 (12): 1796-1808.PubMedCentralCrossRefPubMed
9.
go back to reference Sell H, Eckel J: Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care. 2010, 13 (4): 366-370. 10.1097/MCO.0b013e32833aab7f.CrossRefPubMed Sell H, Eckel J: Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care. 2010, 13 (4): 366-370. 10.1097/MCO.0b013e32833aab7f.CrossRefPubMed
10.
go back to reference Breyne J, Juthier F, Corseaux D, Marechaux S, Zawadzki C, Jeanpierre E, Ung A, Ennezat PV, Susen S, Van Belle E: Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis. 2010, 213 (2): 369-376. 10.1016/j.atherosclerosis.2010.07.047.CrossRefPubMed Breyne J, Juthier F, Corseaux D, Marechaux S, Zawadzki C, Jeanpierre E, Ung A, Ennezat PV, Susen S, Van Belle E: Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis. 2010, 213 (2): 369-376. 10.1016/j.atherosclerosis.2010.07.047.CrossRefPubMed
11.
go back to reference Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, Wang L, Chen Q, Fukuda K, Shen W: Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2010, 9: 70-10.1186/1475-2840-9-70.PubMedCentralCrossRefPubMed Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, Wang L, Chen Q, Fukuda K, Shen W: Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2010, 9: 70-10.1186/1475-2840-9-70.PubMedCentralCrossRefPubMed
12.
go back to reference Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C: Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003, 23 (6): 1029-1034. 10.1161/01.ATV.0000074878.29805.D0.CrossRefPubMed Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C: Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003, 23 (6): 1029-1034. 10.1161/01.ATV.0000074878.29805.D0.CrossRefPubMed
13.
go back to reference Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003, 112 (9): 1318-1331.PubMedCentralCrossRefPubMed Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003, 112 (9): 1318-1331.PubMedCentralCrossRefPubMed
14.
go back to reference Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood E, Jones K, Kawamori R, Cassis L, Tschöp M: Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007, 117 (10): 2877-2888. 10.1172/JCI31986.PubMedCentralCrossRefPubMed Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood E, Jones K, Kawamori R, Cassis L, Tschöp M: Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007, 117 (10): 2877-2888. 10.1172/JCI31986.PubMedCentralCrossRefPubMed
15.
go back to reference Kiefer F, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Säemann M, Geyeregger R, Schlederer M, Kenner L: Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010, 59 (4): 935-946. 10.2337/db09-0404.PubMedCentralCrossRefPubMed Kiefer F, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Säemann M, Geyeregger R, Schlederer M, Kenner L: Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010, 59 (4): 935-946. 10.2337/db09-0404.PubMedCentralCrossRefPubMed
16.
go back to reference Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF: Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol. 2004, 287 (1): G264-G273. 10.1152/ajpgi.00002.2004.CrossRefPubMed Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF: Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol. 2004, 287 (1): G264-G273. 10.1152/ajpgi.00002.2004.CrossRefPubMed
17.
go back to reference Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Schlederer M, Hrabe de Angelis M, Mair M, Kenner L: Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011, 54 (8): 2132-2142. 10.1007/s00125-011-2170-0.PubMedCentralCrossRefPubMed Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Schlederer M, Hrabe de Angelis M, Mair M, Kenner L: Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011, 54 (8): 2132-2142. 10.1007/s00125-011-2170-0.PubMedCentralCrossRefPubMed
18.
go back to reference Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004, 292 (8): 927-934. 10.1001/jama.292.8.927.CrossRefPubMed Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004, 292 (8): 927-934. 10.1001/jama.292.8.927.CrossRefPubMed
19.
go back to reference Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB: Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care. 2010, 33 (11): 2477-2483. 10.2337/dc10-1079.PubMedCentralCrossRefPubMed Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB: Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care. 2010, 33 (11): 2477-2483. 10.2337/dc10-1079.PubMedCentralCrossRefPubMed
20.
go back to reference Schulze M, Liu S, Rimm E, Manson J, Willett W, Hu F: Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr. 2004, 80 (2): 348-356.PubMed Schulze M, Liu S, Rimm E, Manson J, Willett W, Hu F: Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr. 2004, 80 (2): 348-356.PubMed
21.
go back to reference Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB: Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 2009, 89 (4): 1037-1042. 10.3945/ajcn.2008.27140.PubMedCentralCrossRefPubMed Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB: Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 2009, 89 (4): 1037-1042. 10.3945/ajcn.2008.27140.PubMedCentralCrossRefPubMed
22.
go back to reference Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr. 2002, 75 (3): 492-498.PubMed Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr. 2002, 75 (3): 492-498.PubMed
23.
go back to reference Stanhope K, Schwarz J, Keim N, Griffen S, Bremer A, Graham J, Hatcher B, Cox C, Dyachenko A, Zhang W: Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009, 119 (5): 1322-1334. 10.1172/JCI37385.PubMedCentralCrossRefPubMed Stanhope K, Schwarz J, Keim N, Griffen S, Bremer A, Graham J, Hatcher B, Cox C, Dyachenko A, Zhang W: Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009, 119 (5): 1322-1334. 10.1172/JCI37385.PubMedCentralCrossRefPubMed
24.
go back to reference Jalal DI, Smits G, Johnson RJ, Chonchol M: Increased fructose associates with elevated blood pressure. J Am Soc Nephrol. 2010, 21 (9): 1543-1549. 10.1681/ASN.2009111111.PubMedCentralCrossRefPubMed Jalal DI, Smits G, Johnson RJ, Chonchol M: Increased fructose associates with elevated blood pressure. J Am Soc Nephrol. 2010, 21 (9): 1543-1549. 10.1681/ASN.2009111111.PubMedCentralCrossRefPubMed
25.
go back to reference Rebuffe-Scrive M, Surwit R, Feinglos M, Kuhn C, Rodin J: Regional fat distribution and metabolism in a new mouse model (C57BL/6 J) of non-insulin-dependent diabetes mellitus. Metabolism. 1993, 42 (11): 1405-1409. 10.1016/0026-0495(93)90190-Y.CrossRefPubMed Rebuffe-Scrive M, Surwit R, Feinglos M, Kuhn C, Rodin J: Regional fat distribution and metabolism in a new mouse model (C57BL/6 J) of non-insulin-dependent diabetes mellitus. Metabolism. 1993, 42 (11): 1405-1409. 10.1016/0026-0495(93)90190-Y.CrossRefPubMed
26.
go back to reference Chua S, Chung W, Wu-Peng X, Zhang Y, Liu S, Tartaglia L, Leibel R: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996, 271 (5251): 994-996. 10.1126/science.271.5251.994.CrossRefPubMed Chua S, Chung W, Wu-Peng X, Zhang Y, Liu S, Tartaglia L, Leibel R: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996, 271 (5251): 994-996. 10.1126/science.271.5251.994.CrossRefPubMed
27.
go back to reference Nishina P, Naggert J, Verstuyft J, Paigen B: Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metab Clin Exp. 1994, 43 (5): 554-558. 10.1016/0026-0495(94)90195-3.CrossRefPubMed Nishina P, Naggert J, Verstuyft J, Paigen B: Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metab Clin Exp. 1994, 43 (5): 554-558. 10.1016/0026-0495(94)90195-3.CrossRefPubMed
28.
go back to reference Zhang S, Reddick R, Piedrahita J, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992, 258 (5081): 468-471. 10.1126/science.1411543.CrossRefPubMed Zhang S, Reddick R, Piedrahita J, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992, 258 (5081): 468-471. 10.1126/science.1411543.CrossRefPubMed
29.
go back to reference Lichtman AH, Clinton SK, Iiyama K, Connelly PW, Libby P, Cybulsky MI: Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Arterioscler Thromb Vasc Biol. 1999, 19 (8): 1938-1944. 10.1161/01.ATV.19.8.1938.CrossRefPubMed Lichtman AH, Clinton SK, Iiyama K, Connelly PW, Libby P, Cybulsky MI: Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Arterioscler Thromb Vasc Biol. 1999, 19 (8): 1938-1944. 10.1161/01.ATV.19.8.1938.CrossRefPubMed
30.
go back to reference Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, Uno K, Hasegawa Y, Kanzaki M, Yamamoto TT: Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes. 2007, 56 (1): 24-33. 10.2337/db06-0144.CrossRefPubMed Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, Uno K, Hasegawa Y, Kanzaki M, Yamamoto TT: Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes. 2007, 56 (1): 24-33. 10.2337/db06-0144.CrossRefPubMed
31.
go back to reference Hofmann SM, Perez-Tilve D, Greer TM, Coburn BA, Grant E, Basford JE, Tschop MH, Hui DY: Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes. 2008, 57 (1): 5-12.PubMedCentralCrossRefPubMed Hofmann SM, Perez-Tilve D, Greer TM, Coburn BA, Grant E, Basford JE, Tschop MH, Hui DY: Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes. 2008, 57 (1): 5-12.PubMedCentralCrossRefPubMed
32.
go back to reference Bartelt A, Orlando P, Mele C, Ligresti A, Toedter K, Scheja L, Heeren J, Di Marzo V: Altered endocannabinoid signalling after a high-fat diet in Apoe (-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia. 2011, 54 (11): 2900-2910. 10.1007/s00125-011-2274-6.CrossRefPubMed Bartelt A, Orlando P, Mele C, Ligresti A, Toedter K, Scheja L, Heeren J, Di Marzo V: Altered endocannabinoid signalling after a high-fat diet in Apoe (-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia. 2011, 54 (11): 2900-2910. 10.1007/s00125-011-2274-6.CrossRefPubMed
33.
go back to reference Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC: LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab. 2002, 282 (1): E207-E214.PubMed Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC: LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab. 2002, 282 (1): E207-E214.PubMed
34.
go back to reference Ferrannini E, Mari A: How to measure insulin sensitivity. J Hypertens. 1998, 16 (7): 895-906. 10.1097/00004872-199816070-00001.CrossRefPubMed Ferrannini E, Mari A: How to measure insulin sensitivity. J Hypertens. 1998, 16 (7): 895-906. 10.1097/00004872-199816070-00001.CrossRefPubMed
35.
go back to reference Neuhofer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, Hochbrugger EE, Fraisl P, Cinti S, Serhan CN: Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes. 2013, 62 (6): 1945-1956. 10.2337/db12-0828.PubMedCentralCrossRefPubMed Neuhofer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, Hochbrugger EE, Fraisl P, Cinti S, Serhan CN: Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes. 2013, 62 (6): 1945-1956. 10.2337/db12-0828.PubMedCentralCrossRefPubMed
36.
go back to reference Messner B, Zeller I, Ploner C, Frotschnig S, Ringer T, Steinacher-Nigisch A, Ritsch A, Laufer G, Huck C, Bernhard D: Ursolic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis. 2011, 219 (2): 402-408. 10.1016/j.atherosclerosis.2011.05.025.CrossRefPubMed Messner B, Zeller I, Ploner C, Frotschnig S, Ringer T, Steinacher-Nigisch A, Ritsch A, Laufer G, Huck C, Bernhard D: Ursolic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis. 2011, 219 (2): 402-408. 10.1016/j.atherosclerosis.2011.05.025.CrossRefPubMed
37.
go back to reference Burger KN, Beulens JW, van der Schouw YT, Sluijs I, Spijkerman AM, Sluik D, Boeing H, Kaaks R, Teucher B, Dethlefsen C: Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS One. 2012, 7 (8): e43127-10.1371/journal.pone.0043127.PubMedCentralCrossRefPubMed Burger KN, Beulens JW, van der Schouw YT, Sluijs I, Spijkerman AM, Sluik D, Boeing H, Kaaks R, Teucher B, Dethlefsen C: Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS One. 2012, 7 (8): e43127-10.1371/journal.pone.0043127.PubMedCentralCrossRefPubMed
38.
go back to reference Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC: Glycemic index, glycemic load, and chronic disease risk–a meta-analysis of observational studies. Am J Clin Nutr. 2008, 87 (3): 627-637.PubMed Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC: Glycemic index, glycemic load, and chronic disease risk–a meta-analysis of observational studies. Am J Clin Nutr. 2008, 87 (3): 627-637.PubMed
39.
go back to reference Gabrielsson BG, Wikstrom J, Jakubowicz R, Marmon SK, Carlsson NG, Jansson N, Gan LM, Undeland I, Lonn M, Holmang A: Dietary herring improves plasma lipid profiles and reduces atherosclerosis in obese low-density lipoprotein receptor-deficient mice. Int J Mol Med. 2012, 29 (3): 331-337.PubMed Gabrielsson BG, Wikstrom J, Jakubowicz R, Marmon SK, Carlsson NG, Jansson N, Gan LM, Undeland I, Lonn M, Holmang A: Dietary herring improves plasma lipid profiles and reduces atherosclerosis in obese low-density lipoprotein receptor-deficient mice. Int J Mol Med. 2012, 29 (3): 331-337.PubMed
40.
go back to reference Berg A, Scherer P: Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005, 96 (9): 939-949. 10.1161/01.RES.0000163635.62927.34.CrossRefPubMed Berg A, Scherer P: Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005, 96 (9): 939-949. 10.1161/01.RES.0000163635.62927.34.CrossRefPubMed
41.
go back to reference Hartvigsen K, Binder CJ, Hansen LF, Rafia A, Juliano J, Horkko S, Steinberg D, Palinski W, Witztum JL, Li AC: A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007, 27 (4): 878-885. 10.1161/01.ATV.0000258790.35810.02.CrossRefPubMed Hartvigsen K, Binder CJ, Hansen LF, Rafia A, Juliano J, Horkko S, Steinberg D, Palinski W, Witztum JL, Li AC: A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007, 27 (4): 878-885. 10.1161/01.ATV.0000258790.35810.02.CrossRefPubMed
42.
go back to reference Anderson K, Castelli W, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987, 257 (16): 2176-2180. 10.1001/jama.1987.03390160062027.CrossRefPubMed Anderson K, Castelli W, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987, 257 (16): 2176-2180. 10.1001/jama.1987.03390160062027.CrossRefPubMed
43.
go back to reference Ohman MK, Shen Y, Obimba CI, Wright AP, Warnock M, Lawrence DA, Eitzman DT: Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008, 117 (6): 798-805. 10.1161/CIRCULATIONAHA.107.717595.PubMedCentralCrossRefPubMed Ohman MK, Shen Y, Obimba CI, Wright AP, Warnock M, Lawrence DA, Eitzman DT: Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008, 117 (6): 798-805. 10.1161/CIRCULATIONAHA.107.717595.PubMedCentralCrossRefPubMed
44.
go back to reference Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M: C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012, 367 (14): 1310-1320.CrossRefPubMed Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M: C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012, 367 (14): 1310-1320.CrossRefPubMed
45.
go back to reference Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009, 373 (9670): 1175-1182. 10.1016/S0140-6736(09)60447-5.CrossRefPubMed Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009, 373 (9670): 1175-1182. 10.1016/S0140-6736(09)60447-5.CrossRefPubMed
46.
go back to reference Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G: Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008, 149 (3): 1350-1357. 10.1210/en.2007-1312.CrossRefPubMed Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G: Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008, 149 (3): 1350-1357. 10.1210/en.2007-1312.CrossRefPubMed
47.
go back to reference Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S: Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000, 20 (3): 624-628. 10.1161/01.ATV.20.3.624.CrossRefPubMed Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S: Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000, 20 (3): 624-628. 10.1161/01.ATV.20.3.624.CrossRefPubMed
48.
go back to reference Nilsson-Berglund L, Zetterqvist A, Nilsson-Ohman J, Sigvardsson M, González Bosc L, Smith M-L, Salehi A, Agardh E, Fredrikson G, Agardh C-D: Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol. 2010, 30 (2): 218-224. 10.1161/ATVBAHA.109.199299.PubMedCentralCrossRefPubMed Nilsson-Berglund L, Zetterqvist A, Nilsson-Ohman J, Sigvardsson M, González Bosc L, Smith M-L, Salehi A, Agardh E, Fredrikson G, Agardh C-D: Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol. 2010, 30 (2): 218-224. 10.1161/ATVBAHA.109.199299.PubMedCentralCrossRefPubMed
49.
go back to reference de Kleijn DP, Moll FL, Hellings WE, Ozsarlak-Sozer G, de Bruin P, Doevendans PA, Vink A, Catanzariti LM, Schoneveld AH, Algra A: Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol. 2010, 30 (3): 612-619. 10.1161/ATVBAHA.109.194944.CrossRefPubMed de Kleijn DP, Moll FL, Hellings WE, Ozsarlak-Sozer G, de Bruin P, Doevendans PA, Vink A, Catanzariti LM, Schoneveld AH, Algra A: Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol. 2010, 30 (3): 612-619. 10.1161/ATVBAHA.109.194944.CrossRefPubMed
50.
go back to reference Ludwig D: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002, 287 (18): 2414-2423. 10.1001/jama.287.18.2414.CrossRefPubMed Ludwig D: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002, 287 (18): 2414-2423. 10.1001/jama.287.18.2414.CrossRefPubMed
51.
go back to reference Li J, Wang Q, Chai W, Chen MH, Liu Z, Shi W: Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility. Cardiovasc Diabetol. 2011, 10: 117-10.1186/1475-2840-10-117.PubMedCentralCrossRefPubMed Li J, Wang Q, Chai W, Chen MH, Liu Z, Shi W: Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility. Cardiovasc Diabetol. 2011, 10: 117-10.1186/1475-2840-10-117.PubMedCentralCrossRefPubMed
52.
go back to reference Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC: Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology. 2007, 45 (3): 778-788. 10.1002/hep.21499.CrossRefPubMed Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC: Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology. 2007, 45 (3): 778-788. 10.1002/hep.21499.CrossRefPubMed
53.
go back to reference Busserolles J, Rock E, Gueux E, Mazur A, Grolier P, Rayssiguier Y: Short-term consumption of a high-sucrose diet has a pro-oxidant effect in rats. Br J Nutr. 2002, 87 (4): 337-342. 10.1079/BJN2002524.CrossRefPubMed Busserolles J, Rock E, Gueux E, Mazur A, Grolier P, Rayssiguier Y: Short-term consumption of a high-sucrose diet has a pro-oxidant effect in rats. Br J Nutr. 2002, 87 (4): 337-342. 10.1079/BJN2002524.CrossRefPubMed
54.
go back to reference Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, Cros G, Azay J: Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis. 2005, 179 (1): 43-49. 10.1016/j.atherosclerosis.2004.10.018.CrossRefPubMed Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, Cros G, Azay J: Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis. 2005, 179 (1): 43-49. 10.1016/j.atherosclerosis.2004.10.018.CrossRefPubMed
55.
go back to reference Johnson R, Segal M, Sautin Y, Nakagawa T, Feig D, Kang D-H, Gersch M, Benner S, Sánchez-Lozada L: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007, 86 (4): 899-906.PubMed Johnson R, Segal M, Sautin Y, Nakagawa T, Feig D, Kang D-H, Gersch M, Benner S, Sánchez-Lozada L: Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007, 86 (4): 899-906.PubMed
56.
go back to reference Ushijima K, Riby JE, Fujisawa T, Kretchmer N: Absorption of fructose by isolated small intestine of rats is via a specific saturable carrier in the absence of glucose and by the disaccharidase-related transport system in the presence of glucose. J Nutr. 1995, 125 (8): 2156-2164.PubMed Ushijima K, Riby JE, Fujisawa T, Kretchmer N: Absorption of fructose by isolated small intestine of rats is via a specific saturable carrier in the absence of glucose and by the disaccharidase-related transport system in the presence of glucose. J Nutr. 1995, 125 (8): 2156-2164.PubMed
57.
go back to reference Merat S, Casanada F, Sutphin M, Palinski W, Reaven P: Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol. 1999, 19 (5): 1223-1230. 10.1161/01.ATV.19.5.1223.CrossRefPubMed Merat S, Casanada F, Sutphin M, Palinski W, Reaven P: Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol. 1999, 19 (5): 1223-1230. 10.1161/01.ATV.19.5.1223.CrossRefPubMed
Metadata
Title
An accelerated mouse model for atherosclerosis and adipose tissue inflammation
Authors
Angelika Neuhofer
Bernhard Wernly
Lukas Leitner
Alisina Sarabi
Nicole G Sommer
Günther Staffler
Maximilian Zeyda
Thomas M Stulnig
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-13-23

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue